Eikon Therapeutics, Inc. Overview
Pro stress-test →Founded in 2019 by a team of scientists including Nobel laureate Eric Betzig, Eikon is built on the premise that directly visualizing molecular events inside living cells can revolutionize how new medicines – especially cancer treatments – are discovered. Eikon Therapeutics is a star-studded biotechnology startup that raised more than $1 billion in venture funding, and secured $381 million through an initial public offering in February 2026, selling over 21 million shares at $18 apiece, with shares beginning trading under the ticker symbol "EIKN."
Strategic Profile
Pro stress-test →The company is run by a group of former Merck & Co. executives including ex-research chief Roger Perlmutter and one-time clinical development leader Roy Baynes. Eikon's unique drug discovery platform marries advanced live-cell imaging technology with therapeutic development, using super-resolution fluorescence microscopy and single-molecule tracking to observe how proteins and other drug targets move and interact within live cells in real time. Eikon is a late-stage clinical biopharmaceutical company focused on developing medicines for serious unmet medical needs, with an initial emphasis on oncology.
Competitive Landscape
Pro stress-test →Eikon's PARP inhibitors in Phase 1 are designed to be more selective than similar, available drugs like Merck and AstraZeneca's Lynparza. The company operates in the increasingly competitive oncology space alongside established players like Merck, AstraZeneca, and Bristol Myers Squibb, but differentiates through its proprietary live-cell imaging discovery platform and in-licensed, clinical-stage assets. Direct competitors in the platform-based drug discovery space include companies leveraging AI, structural biology, and computational approaches to accelerate oncology development.
Industry Context
Eikon Therapeutics, Inc. operates in Oncology drug development and live-cell imaging platforms.
Key facts
Founded: 2019 · Headquarters: Hayward, US · Employees: N/A · Revenue: N/A · Market cap: $590.7M